COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 12 FDA records to the applicant name Medtronic. The collection includes 3 510(k) clearances. It includes 1 original PMA approval. 6 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Nov 20, 2012 to Oct 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code DSQ appears in 9 of the 12 linked filings. The collection spans 3 FDA product codes and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P100047, with 9 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 8200 Coral Sea St. NE, Mounds View, MN, 55112, US. Recorded on K261792, decision dated Oct 23, 2026.
Device categories in this collection
Ventricular (Assist) Bypass; Suture, Absorbable, Synthetic, Polyglycolic Acid; Filter, Blood, Cardiopulmonary Bypass, Arterial Line.
Changes described in PMA records
The FDA recorded an approval decision on 2026-09-23 for P100047/S241, a Special (Immediate Track) supplement to the HeartWare® HVAD System premarket approval held by Medtronic. The device falls under the ventricular (assist) bypass category, cardiovascular specialty, product code DSQ. The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename.
The recorded scope is limited to labeling: updates reflecting previously approved design changes, strengthened existing cybersecurity warnings, and editorial changes. This action does not constitute a new approval of the HVAD System as a whole, and the source record does not specify which labeling sections changed, the wording of the cybersecurity warnings, or the design changes referenced. No supporting documents were included, so those details remain unknown from this record.
FDA approval-order wording
Approval for labeling updates to reflect previously approved design changes, strengthen existing cybersecurity warnings, and make editorial changes.
Sep 23, 2026 · Special (Immediate Track)FDA’s recorded scope: Approval for end-user sterilization of the Sewing Ring Wrench
Aug 5, 2026 · Normal 180 Day TrackFDA’s recorded scope: Approval for the following design and manufacturing changes related to the HeartWare Ventricular Assist Systems Battery Charger AC Adapter: i) Component changes on the AC Adapter printed circuit board assembly (PCBA), ii) Addition of a ferrite component to the AC Adapter cable, and iii) Implementation of a new rework process for replacing the power supply of the AC Adapter.
Jul 28, 2026 · Normal 180 Day TrackFDA’s recorded scope: addition of an alternate component for an integrated circuit on the HVAD controller
May 14, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for a new HVAD battery charger, a new packaging configuration for the HVAD power cords, and labeling updates.
Apr 10, 2026 · Normal 180 Day TrackSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.